176 related articles for article (PubMed ID: 22404399)
1. Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma.
Vail DM; Husbands BD; Kamerling SG; Simpson H; Kurzman ID; McDonnell A
J Vet Intern Med; 2012; 26(3):608-13. PubMed ID: 22404399
[TBL] [Abstract][Full Text] [Related]
2. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
[TBL] [Abstract][Full Text] [Related]
3. An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs.
Fiocchi SC; Selting KA; Rosenberg MP; Kolli P; Lenaz G; Henry C
J Vet Intern Med; 2011; 25(4):897-902. PubMed ID: 21736623
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Olivier G; Clavert A; Lacotte-Thierry L; Gardembas M; Escoffre-Barbe M; Brion A; Cumin I; Legouffe E; Solal-Celigny P; Chabin M; Ingrand P; Colombat P; Delwail V
Am J Hematol; 2014 Nov; 89(11):1024-9. PubMed ID: 25052698
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.
Silver M; Rusk A; Phillips B; Beck E; Jankowski M; Philibert J; Hahn K; Hershey E; McKeegan E; Bauch J; Krivoshik A; Khanna C
J Vet Intern Med; 2012; 26(2):349-54. PubMed ID: 22369215
[TBL] [Abstract][Full Text] [Related]
7. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial.
Boulin M; Hillon P; Cercueil JP; Bonnetain F; Dabakuyo S; Minello A; Jouve JL; Lepage C; Bardou M; Wendremaire M; Guerard P; Denys A; Grandvuillemin A; Chauffert B; Bedenne L; Guiu B
Aliment Pharmacol Ther; 2014 Jun; 39(11):1301-13. PubMed ID: 24738629
[TBL] [Abstract][Full Text] [Related]
8. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
Leukemia; 1997 Dec; 11 Suppl 5():S15-21. PubMed ID: 9436933
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of, and toxicoses associated with, oral idarubicin administration in cats with neoplasia.
Moore AS; Ruslander D; Cotter SM; Rand WM; L'Heureux DA
J Am Vet Med Assoc; 1995 May; 206(10):1550-4. PubMed ID: 7775231
[TBL] [Abstract][Full Text] [Related]
10. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
Leukemia; 1996 Apr; 10(4):707-12. PubMed ID: 8618451
[TBL] [Abstract][Full Text] [Related]
11. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of idarubicin dose escalation for remission induction therapy in acute myeloid leukemia.
Lee MH; Kim SY
Leuk Lymphoma; 2016 Oct; 57(10):2268-74. PubMed ID: 26750985
[TBL] [Abstract][Full Text] [Related]
13. An open-label phase 1 dose-escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors.
Marconato L; Finotello R; Bonfanti U; Dacasto M; Beatrice L; Pizzoni S; Leone VF; Balestra G; Furlanello T; Rohrer Bley C; Aresu L
J Vet Intern Med; 2015; 29(2):620-5. PubMed ID: 25818216
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose escalation of single-agent vinblastine in dogs.
Bailey DB; Rassnick KM; Kristal O; Chretin JD; Balkman CE
J Vet Intern Med; 2008; 22(6):1397-402. PubMed ID: 19000250
[TBL] [Abstract][Full Text] [Related]
15. An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma.
Anota A; Boulin M; Dabakuyo-Yonli S; Hillon P; Cercueil JP; Minello A; Jouve JL; Paoletti X; Bedenne L; Guiu B; Bonnetain F
BMJ Open; 2016 Jun; 6(6):e010696. PubMed ID: 27342239
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.
Fukushima T; Yamashita T; Goto N; Ueda T; Okabe KI; Kuraishi Y; Ohno R; Urabe A; Ogawa M
Int J Hematol; 2001 Oct; 74(3):297-302. PubMed ID: 11721966
[TBL] [Abstract][Full Text] [Related]
19. Incidence of sterile hemorrhagic cystitis in dogs receiving cyclophosphamide orally for three days without concurrent furosemide as part of a chemotherapeutic treatment for lymphoma: 57 cases (2007-2012).
Best MP; Fry DR
J Am Vet Med Assoc; 2013 Oct; 243(7):1025-9. PubMed ID: 24050570
[TBL] [Abstract][Full Text] [Related]
20. Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.
Guiu B; Jouve JL; Schmitt A; Minello A; Bonnetain F; Cassinotto C; Piron L; Cercueil JP; Loffroy R; Latournerie M; Wendremaire M; Lepage C; Boulin M
J Hepatol; 2018 Jun; 68(6):1163-1171. PubMed ID: 29427728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
